ATP6V1E1

Across TCGA pan-cancer cohorts, ATP6V1E1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP6V1E1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP6V1E1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATP6V1E1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where ATP6V1E1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	1.000	0.451	.016	30	view →
LUAD	OS	Median	All	0.521	0.843	.002	21	view →
COAD	DFS	Median	III,IV	0.826	1.000	.023	12	view →
LSCC	DFS	Median	II,III,IV	0.971	0.877	.014	4	view →
HNSC	DFS	Tertile	III,IV	0.911	1.000	.036	4	view →
GBM	DFS	Median	All	0.839	0.649	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP6V1E1–CCRCC (OS)

Open the CCRCC breakdown →